CJC-1295 No DAC + Ipamorelin 10mg (CJC-1295 DAC)
Research Use Only
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Purity / Result
99.03% +/- 0.18%
Mass / Quantity
CJC-1295 No DAC 9.37 mg; Ipamorelin 10.98 mg
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
By combining these two peptides, enhanced effects are produced because they stimulate the growth hormone axis via two different mechanisms. CJC-1295 (No DAC) has demonstrated positive benefits on bone health, lean body mass, insulin resistance, and muscle growth through GHRH receptor stimulation. Ipamorelin is known to improve bone health, boost muscle repair, stimulate insulin release from the pancreas, and improve bowel motility and gastric function. Ipamorelin raises baseline GH levels such that CJC-1295 produces both higher peaks and higher troughs while preserving normal pulsatile secretion. The net effect is a higher set point for the normal ebb and flow of GH, resulting in improved lean body mass, better muscle development, improved insulin utilization, and overall better metabolic function.
Frequently Bought Together
CJC-1295 No DAC + Ipamorelin 10mg (5+5)
10mg
$49 USD
Bundle & Save
$84 USD
Save $4 USD
$134 USD
Save $14 USD
$179 USD
Save $29 USD
$214 USD
Save $44 USD
Click any product above to toggle selection
Related Peptides
CJC-1295 and Ipamorelin Blend
Ipamorelin is one of the most selective growth hormone (GH) secretagogues known and a potent agonist of the ghrelin/growth hormone secretagogue receptor. It has been heavily researched in a number of settings and is known to improve bone health, boost muscle repair and development, stimulate insulin release from the pancreas, and improve bowel motility and gastric function.
CJC-1295 also causes the release of GH, but it does so by stimulating the growth hormone releasing hormone receptor. It is also highly selective and has demonstrated positive benefits on bone health, lean body mass, insulin resistance, and muscle growth and development. By combining the two peptides, it may be possible to produce enhanced effects because they stimulate the growth hormone axis via two different mechanisms. Research in animal models using both peptides is likely to show increased benefit without substantially increased side effects.
Ipamorelin is likely to raise baseline levels of GH such that CJC-1295 will be able to produce both higher peaks and higher troughs while preserving normal growth hormone pulsatile secretion. The net effect of combining the peptides would be a higher set point for the normal ebb and flow of GH, resulting in improved lean body mass, better muscle development, improved use of insulin, and overall better metabolic function.
CJC-1295/Ipamorelin Summary
CJC-1295 and Ipamorelin exhibit minimal side effects and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. CJC-1295/Ipamorelin for sale at Volta Peptides is limited to educational and scientific research only, not for human consumption. Only buy CJC-1295/Ipamorelin if you are a licensed researcher.
Article Author
B.S. in molecular biology.
Scientific Journal Author
Completed Post-Doctoral Research at the University of California, Berkeley. Studied CJC-1295 as a long lasting GRF analog and held leadership positions at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Brings 30 years of executive and scientific leadership experience.
Referenced Citations
- 1K. Raun et al., "Ipamorelin, the first selective growth hormone secretagogue," Eur. J. Endocrinol., vol. 139, no. 5, pp. 552-561, Nov. 1998.
- 2N. B. Andersen et al., "The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats," Growth Horm. IGF Res., vol. 11, no. 5, pp. 266-272, Oct. 2001.
- 3J. Svensson et al., "The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats," J. Endocrinol., vol. 165, no. 3, pp. 569-577, Jun. 2000.
- 4E. Adeghate and A. S. Ponery, "Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats," Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403-406, Dec. 2004.
- 5D. E. Beck et al., "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients," Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527-1534, Dec. 2014.
- 6B. Greenwood-Van Meerveld et al., "Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus," J. Exp. Pharmacol., vol. 4, pp. 149-165, Oct. 2012.
- 7M. Alba et al., "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse," Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006.
- 8M. Ionescu and L. A. Frohman, "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog," J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792-4797, Dec. 2006.
- 9M. C. Van Hout and E. Hearne, "Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions," Subst. Use Misuse, vol. 51, no. 1, pp. 73-84, Jan. 2016.
- 10Jette, Lucie et al., "hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog," 2005.
Disclaimer
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are furnished for in-vitro studies only. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.
Related Research News
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.